Coronary/Structural Heart

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes

– Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction – Treatment of heart failure is an important unmet need with over half of those diagnosed dying within five […]

Ontrak achieves HITRUST CSF® Certification to further mitigate risk in third-party privacy, security, and compliance

HITRUST CSF Certification validates Ontrak is committed to meeting key regulations and protecting sensitive information SANTA MONICA, Calif.–(BUSINESS WIRE)–Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that the company’s data pipeline system, eOntrak Case Management System and supporting technology infrastructure have […]

CHF Solutions Further Expands Commercial Presence in the Middle East with Distribution Arrangement for Israel and Palestine

EDEN PRAIRIE, Minn., July 30, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS) today announced the signing of a distribution agreement with SysteMedic Ltd., covering Israel and Palestine, representing the second distribution partnership in the Middle East region.  Ultrafiltration therapy is now available in 16 countries outside the U.S. Ninety […]

Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes

– Jardiance (empagliflozin) significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction – Treatment of heart failure is an important unmet need with over half of those diagnosed […]

First successful trans-femoral mitral valve repair device DragonFly™ performed in China

HANGZHOU, China, July 29, 2020 /PRNewswire/ — On July 23, 2020, Professor Jian’an Wang’s team at the Second Affiliated Hospital of Zhejiang University School of Medicine successfully completed the world’s first human clinical application of the transcatheter mitral valve repair system (DragonFly™) developed by Hangzhou Valgen Medtech Co.,Ltd. This marks a major breakthrough […]

Keystone Heart, A Venus Medtech Company, Announces First Commercial Case Performed Worldwide with the TriGUARD 3™ Cerebral Embolic Protection Device

TAMPA, Fla., July 29, 2020 /PRNewswire/ — Keystone Heart, LTD., a medical device innovator driven to redefine the standard of structural heart care, today announced completion of the first worldwide commercial case using the TriGUARD 3™ Cerebral Embolic Protection (CEP) Device. Pieter Stella, MD, Assistant Professor, Medical Department of Cardiology, at UMC Utrecht in the […]

Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890

PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a Phase 2 clinical study. The study is evaluating the efficacy, safety, and tolerability […]

CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data

MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ — CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Data Monitoring Committee (DMC) of the REFRESH 2-AKI trial has completed a comprehensive favorable review […]

A startup that monitors heart health with a toilet seat joins Innovators’ Network

Heart Health Intelligence is the latest member of the American Heart Association’s Center for Health Technology & Innovation Innovators’ Network ROCHESTER, N.Y., July 28, 2020 (GLOBE NEWSWIRE) — Heart Health Intelligence (HHI) has joined the American Heart Association’s Center for Health Technology & Innovation’s (the Center) Innovators’ Network. The Center is focused on building and […]

Endonovo Therapeutics Announces Significant Results From Study Showing 70% Reduction of Morphine Equivalent Dose and 2 Day Reduction of Length of Stay at Hospitals Using SofPulse®

LOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), today announced that an investigator initiated study, authored by Dr. Samir Awad, Professor of Surgery at Baylor College of Medicine, entitled ‘The Impact of Pulsed Electromagnetic Field (SofPulse®) on Postoperative Pain in Patients […]